But, as Feuerstein details, this sounds like a lot more than the usual bio-mess-up.

FORBES: Biotech's Revolving Door

The news was first reported by The Street reporter Adam Feuerstein.

FORBES: FDA Approves Vascepa, A New Fish Oil Pill From Amarin

"What a great privilege to be at the controls of such a great airplane on its first flight, " said Feuerstein.

ENGADGET: Boeing's biggest jet takes flight, promises lowest 'seat mile' cost of any commercial airliner

Adam Feuerstein at TheStreet says the market was wrong, because t his means the FDA is actively considering the idea.

FORBES: A Key Exchange On Sarepta Therapeutics' Promising Muscular Dystrophy Drug

"We're not trying to re-invent every aspect of the science, " said Seth Feuerstein, president of Carigent Therapeutics in New Haven, Conn.

FORBES: Magazine Article

Adam Feuerstein from TheStreet.com seriously buries the lead in his Biotech Stock Mailbag column, waiting until page three to get to this gem.

FORBES: Biotech's Revolving Door

With 747 Chief Pilot Mark Feuerstein and Capt.

ENGADGET: Boeing's biggest jet takes flight, promises lowest 'seat mile' cost of any commercial airliner

In fact, in an accompanying editorial, The Street columnist Adam Feuerstein and Mark Ratain of the University of Chicago calculated market caps at 120 days before public disclosure and found that values were 80-fold greater for those with positive results than those with negative trials.

FORBES: Why Pharma Stocks May Rise Before Trial Data Is Released